Ignyta announces initiation of STARTRK-1 global phase I/II clinical trial of RXDX-101
Ignyta announced the multicenter initiation of the company's global Phase I/II clinical trial of RXDX-101, its proprietary oral tyrosine kinase inhibitor targeting multiple solid tumor indications. This clinical trial is a Phase I/IIa, multicenter, single-arm, open-label clinical trial. July 21, 2014